If you want to change the future of cancer, let’s talk. It is our goal to bring this potentially lifesaving treatment approach to as many people with cancer as possible. ![]() We recognize the urgency of our mission and work hard every day to ensure that each step of the journey to bring a patient’s own cells back to them is executed with the utmost precision and care. As we look to tomorrow, we’re focused on advancing technologies that could someday impact a broader range of disease states. We are proud to be a leader in engineered T cell therapy, but we recognize that today is just the beginning. Since 2009, members of our team have been at the forefront of cancer immunotherapy. Currently, Naren Kadaba works as a Head Vice President, Manufacturing Operations & Site at Kite Pharma. ![]() So when we say patients are at the center of everything we do, we truly mean it. Our cell therapy specialists are physically holding patients’ cells in their hands and ensuring they get safely back to that same patient for reinfusion. That sense of connection to the patients we serve is at the heart of everything we do. With CAR T-cell therapy, we are reengineering a patient’s own immune cells to fight cancer - one patient at a time. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. ![]() Our personalized approach is what sets us apart from other health and life science companies. Under the terms of the agreement, Amgen will contribute cancer targets while Kite will offer up its CAR drug discovery platform, R&D and manufacturing capabilities, as well as its. Everyone at Kite is grounded by one common goal – curing cancer. US biotech firm Amgen and early cancer drug discovery company Kite Pharma have signed a major research and development deal focused on therapeutic oncology vaccines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |